GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » Debt-to-EBITDA

Qurient Co (XKRX:115180) Debt-to-EBITDA : -0.01 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Qurient Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩188 Mil. Qurient Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩44 Mil. Qurient Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ₩-22,103 Mil. Qurient Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Qurient Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:115180' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06   Med: -0.04   Max: -0.01
Current: -0.01

During the past 10 years, the highest Debt-to-EBITDA Ratio of Qurient Co was -0.01. The lowest was -0.06. And the median was -0.04.

XKRX:115180's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs XKRX:115180: -0.01

Qurient Co Debt-to-EBITDA Historical Data

The historical data trend for Qurient Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co Debt-to-EBITDA Chart

Qurient Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.06 -0.04 -0.03 -0.02

Qurient Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.02 -0.03 -0.01

Competitive Comparison of Qurient Co's Debt-to-EBITDA

For the Biotechnology subindustry, Qurient Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qurient Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qurient Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Qurient Co's Debt-to-EBITDA falls into.



Qurient Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Qurient Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(298.207 + 35.496) / -21411.506
=-0.02

Qurient Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(187.878 + 43.762) / -22102.76
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Qurient Co  (XKRX:115180) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Qurient Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Qurient Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Qurient Co (XKRX:115180) Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co (XKRX:115180) Headlines

No Headlines